QQ客服 官方微博 反馈留言

浏览/检索结果: 共15条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文 BMC CANCER, 2022, 卷号: 22 作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong 收藏  |  浏览/下载：21/0  |  提交时间：2022/12/23 Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong 收藏  |  浏览/下载：38/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation 期刊论文 THERANOSTICS, 2020, 卷号: 10, 期号: 14, 页码: 6122-6135 作者:  Yin, Weimin;  Zhao, Yuge;  Kang, Xuejia;  Zhao, Pengfei;  Zhao, Xuhong 收藏  |  浏览/下载：44/0  |  提交时间：2020/07/01 brain targeting delivery  tumor-associated macrophage  non-small cell lung cancer (NSCLC)  drug resistance  tyrosine kinase inhibitors (TKI)  EGFR T790M mutation   Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, 期刊论文 2019, 卷号: 42, 期号: 5, 页码: 432-439 作者:  Song, Yong;  Wu, Yi-Long;  Cao, Le-Jie;  Chen, Jian-Hua;  Ma, Zhi-Yong 收藏  |  浏览/下载：31/0  |  提交时间：2020/01/03 re-challenge  gefitinib  T790M mutation  progression-free survival  EGFR-TKI  NSCLC   Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR(T790M)-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery 期刊论文 SMALL, 2018, 卷号: 14, 期号: 47 作者:  Yin, Weimin;  Yu, Xiaolu;  Kang, Xuejia;  Zhao, Yuge;  Zhao, Pengfei 收藏  |  浏览/下载：100/0  |  提交时间：2019/01/08 antiangiogenesis  EGFR(T790M) mutation  PD-L1 nanobody  simvastatin  tumor-associated macrophage   YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)-mutant resistance in vitro and in vivo 期刊论文 CANCER MEDICINE, 2018, 卷号: 7, 期号: 4, 页码: 1430-1439 作者:  Zhang, Zhang;  Zou, Jian;  Yu, Lei;  Luo, Jinfeng;  Li, Yan 收藏  |  浏览/下载：70/0  |  提交时间：2019/01/08 EGFR inhibitor  lung cancer  pharmacokinetic  selectively  T790M mutation   Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy 期刊论文 2018, 卷号: 11, 页码: 7513-7519 作者:  Wang, Hanping;  Zhang, Li;  Si, Xiaoyan;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 re-biopsy  T790M mutation  resistant mechanism  EGFR-TKI  icotinib  non-small-cell lung cancer   Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation 期刊论文 2018, 卷号: 122, 页码: 1-6 作者:  Wang Hanping;  Zhang Li;  Hu Pei;  Zheng Xin;  Si Xiaoyan 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 Brain metastases  Cerebrospinal fluid  Penetration rate  T790M mutation  Third generation EGFR TKI   Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment 期刊论文 2018, 卷号: 423, 页码: 9-15 作者:  Li, Weihua;  Qiu, Tian;  Guo, Lei;  Ling, Yun;  Gao, Yibo 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/03 Non-small cell lung cancer  Primary EGFR T790M mutation  Acquired EGFR T790M mutation  Sensitizing EGFR mutation  Mutant allele frequency   EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs 期刊论文 Cancer Letters, 2017, 卷号: Vol.403, 页码: 186-194 作者:  Liang, Z.;  Cheng, Y.;  Chen, Y.;  Hu, Y.;  Liu, W.-P. 收藏  |  浏览/下载：4/0  |  提交时间：2019/02/25 Drug  resistance  EGFR  T790M  mutation  NSCLC  Tyrosine  kinase  inhibitors